WO2003062269A3 - Agonistes du recepteur 2 du facteur de liberation de la corticotropine - Google Patents

Agonistes du recepteur 2 du facteur de liberation de la corticotropine Download PDF

Info

Publication number
WO2003062269A3
WO2003062269A3 PCT/US2003/001461 US0301461W WO03062269A3 WO 2003062269 A3 WO2003062269 A3 WO 2003062269A3 US 0301461 W US0301461 W US 0301461W WO 03062269 A3 WO03062269 A3 WO 03062269A3
Authority
WO
WIPO (PCT)
Prior art keywords
releasing factor
corticotropin releasing
agonists
factor receptor
effective
Prior art date
Application number
PCT/US2003/001461
Other languages
English (en)
Other versions
WO2003062269A2 (fr
Inventor
Robert Joseph Isfort
Wieslaw Adam Mazur
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BR0306838-2A priority Critical patent/BR0306838A/pt
Priority to AU2003205197A priority patent/AU2003205197B2/en
Priority to NZ533600A priority patent/NZ533600A/en
Priority to MXPA04006885A priority patent/MXPA04006885A/es
Priority to BR0306878-1A priority patent/BR0306878A/pt
Priority to KR1020047011051A priority patent/KR100735586B1/ko
Priority to SI200330360T priority patent/SI1465921T1/sl
Priority to IL16243103A priority patent/IL162431A0/xx
Application filed by Procter & Gamble filed Critical Procter & Gamble
Priority to DE60307044T priority patent/DE60307044T2/de
Priority to JP2003562146A priority patent/JP4508649B2/ja
Priority to EP03703867A priority patent/EP1465921B1/fr
Priority to CA2470743A priority patent/CA2470743C/fr
Publication of WO2003062269A2 publication Critical patent/WO2003062269A2/fr
Publication of WO2003062269A3 publication Critical patent/WO2003062269A3/fr
Priority to NO20043366A priority patent/NO20043366L/no
Priority to CY20061101051T priority patent/CY1106133T1/el
Priority to IL197774A priority patent/IL197774A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des dérivés isolés du facteur de libération de la corticotropine et des acides nucléiques codant lesdits dérivés. Ces dérivés sont efficaces dans le traitement de troubles modulés par le récepteur 2 du facteur de libération de la corticotropine, tels qu'une dystrophie musculaire.
PCT/US2003/001461 2002-01-16 2003-01-16 Agonistes du recepteur 2 du facteur de liberation de la corticotropine WO2003062269A2 (fr)

Priority Applications (15)

Application Number Priority Date Filing Date Title
DE60307044T DE60307044T2 (de) 2002-01-16 2003-01-16 Agonisten des corticotropin-freisetzenden faktor rezeptors 2
AU2003205197A AU2003205197B2 (en) 2002-01-16 2003-01-16 Corticotropin releasing factor receptor 2 agonists
JP2003562146A JP4508649B2 (ja) 2002-01-16 2003-01-16 コルチコトロピン放出因子レセプター２アゴニスト
BR0306878-1A BR0306878A (pt) 2002-01-16 2003-01-16 Peptìdeo não-agonista do receptor de fator de liberação de corticotropina 2, ácido nucleico e anticorpo isolados, composição farmacêutica e kit compreendendo o referido peptìdeo e uso do referido peptìdeo e ácido nucleico na fabricação de um medicamento
KR1020047011051A KR100735586B1 (ko) 2002-01-16 2003-01-16 코르티코트로핀 방출 인자 2 수용체 작용제
SI200330360T SI1465921T1 (sl) 2002-01-16 2003-01-16 Agonisti receptorja 2 kortikotropin sproscujocegafaktorja
IL16243103A IL162431A0 (en) 2002-01-16 2003-01-16 Corticotropin releasing factor 2 receptor agonists
BR0306838-2A BR0306838A (pt) 2002-01-16 2003-01-16 Peptìdeo não-nativo, ácido nucléico isolado, composição farmacêutica e kit para prevenção ou tratamento de uma doença modulada por crf2r
NZ533600A NZ533600A (en) 2002-01-16 2003-01-16 Corticotropin releasing factor 2 receptor agonist for use in CRF2R modulated muscular dystropy or muscle atrophy
MXPA04006885A MXPA04006885A (es) 2002-01-16 2003-01-16 Agonistas del receptor 2 del factor de liberacion de corticotropina.
EP03703867A EP1465921B1 (fr) 2002-01-16 2003-01-16 Agonistes du recepteur 2 du facteur de liberation de la corticotropine
CA2470743A CA2470743C (fr) 2002-01-16 2003-01-16 Agonistes du recepteur 2 du facteur de liberation de la corticotropine
NO20043366A NO20043366L (no) 2002-01-16 2004-08-13 Kortikotropinfrigjorende faktor-2 reseptoragonister
CY20061101051T CY1106133T1 (el) 2002-01-16 2006-07-28 Αγωνιστες υποδοχεα 2 παραγοντα απελευθερωσης κορτικοτροπινης
IL197774A IL197774A0 (en) 2002-01-16 2009-03-24 Corticotropin releasing factor 2 receptor agonists

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US34911702P 2002-01-16 2002-01-16
US60/349,117 2002-01-16
US37633702P 2002-04-29 2002-04-29
US60/376,337 2002-04-29
US38889502P 2002-06-14 2002-06-14
US60/388,895 2002-06-14
US41198802P 2002-09-19 2002-09-19
US60/411,988 2002-09-19

Publications (2)

Publication Number Publication Date
WO2003062269A2 WO2003062269A2 (fr) 2003-07-31
WO2003062269A3 true WO2003062269A3 (fr) 2003-11-06

Family

ID=27617822

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/US2003/001461 WO2003062269A2 (fr) 2002-01-16 2003-01-16 Agonistes du recepteur 2 du facteur de liberation de la corticotropine
PCT/US2003/001451 WO2003062268A2 (fr) 2002-01-16 2003-01-16 Agonistes du recepteur de facteur 2 de liberation de la corticotropine
PCT/US2003/001454 WO2003062277A1 (fr) 2002-01-16 2003-01-16 Agonistes du recepteur du facteur de liberation 2 de la corticotropine

Family Applications After (2)

Application Number Title Priority Date Filing Date
PCT/US2003/001451 WO2003062268A2 (fr) 2002-01-16 2003-01-16 Agonistes du recepteur de facteur 2 de liberation de la corticotropine
PCT/US2003/001454 WO2003062277A1 (fr) 2002-01-16 2003-01-16 Agonistes du recepteur du facteur de liberation 2 de la corticotropine

Country Status (30)

Country Link
US (7) US7192924B2 (fr)
EP (4) EP1724283B1 (fr)
JP (3) JP4508649B2 (fr)
KR (3) KR100735586B1 (fr)
CN (3) CN1617887A (fr)
AR (3) AR038144A1 (fr)
AT (4) ATE398632T1 (fr)
AU (2) AU2003237419B2 (fr)
BR (3) BR0306826A (fr)
CA (3) CA2470656C (fr)
CY (1) CY1106133T1 (fr)
DE (4) DE60321730D1 (fr)
DK (2) DK1465921T3 (fr)
ES (4) ES2309909T3 (fr)
HK (1) HK1078095A1 (fr)
IL (5) IL162530A0 (fr)
MA (3) MA27590A1 (fr)
MX (3) MXPA04006883A (fr)
MY (1) MY140306A (fr)
NO (3) NO20043366L (fr)
NZ (3) NZ533599A (fr)
PE (3) PE20030974A1 (fr)
PL (3) PL371364A1 (fr)
PT (2) PT1465923E (fr)
RU (1) RU2294333C2 (fr)
SA (3) SA03230564B1 (fr)
SI (1) SI1465921T1 (fr)
TW (3) TW200302278A (fr)
WO (3) WO2003062269A2 (fr)
ZA (1) ZA200404995B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001289916A1 (en) * 2000-09-22 2002-04-02 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Methods for improving the antagonistic/agonistic properties of peptidic antagonists/agonists of the corticotropin-releasing factor receptor (crfr)
US7192924B2 (en) * 2002-01-16 2007-03-20 The Procter & Gamble Company Corticotropin releasing factor 2 receptor agonists
WO2005103690A2 (fr) * 2004-04-24 2005-11-03 Bayer Healthcare Ag Diagnostic et therapeutique de maladies associees au recepteur de l'hormone de liberation de la corticotropine 2 (crhr2)
AU2006235045A1 (en) * 2005-03-30 2006-10-19 J. Craig Venter Institute, Inc. Haemophilus influenzae type b
WO2007090087A2 (fr) * 2006-01-27 2007-08-09 Research Development Foundation Inhibiteurs du recepteur 2 du facteur de liberation de la corticotrophine et ses utilisations
KR20100061478A (ko) * 2007-09-11 2010-06-07 몬도바이오테크 래보래토리즈 아게 치료제로서의 세크레틴 및 임의의 유로딜라틴의 용도
WO2009033773A2 (fr) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009046874A1 (fr) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Polythérapie de peptide potentialisateur de la trh et de stresscopine
EA201170647A1 (ru) * 2008-11-04 2011-12-30 Янссен Фармацевтика Нв Пептиды-агонисты crhr2 и их использование
EP2206726A1 (fr) * 2009-01-08 2010-07-14 Universite Joseph Fourier Outils non invasifs pour la détection de plaques athérosclérotique vulnérables
MX2012005262A (es) * 2009-11-04 2012-09-28 Janssen Pharmaceutica Nv Metodo para tratar la insuficiencia cardiaca con petidos tipo estrescopina.
WO2013063046A1 (fr) 2011-10-24 2013-05-02 Research Development Foundation Procédés d'augmentation de la sécrétion d'insuline par costimulation des récepteurs du facteur de libération de la corticotropine
CN104220098B (zh) 2012-02-14 2018-04-10 加利福尼亚大学董事会 用于心血管疾病和其它病况的旁分泌基因的全身性递送和受调节的表达
JOP20170153A1 (ar) 2016-07-15 2019-01-30 Lilly Co Eli نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
AU2017345785A1 (en) * 2016-10-20 2019-05-16 Cortene Inc. Methods of treating diseases resulting from a maladapted stress response
CN110755434B (zh) * 2018-07-27 2022-03-15 中国医学科学院药物研究所 化合物palosuran防治骨骼肌萎缩等疾病的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997032898A1 (fr) * 1996-03-06 1997-09-12 The Regents Of The University Of California Analogues anti-inflammatoires de crf, leur composition et leur emploi

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5235036A (en) 1991-05-31 1993-08-10 The Salk Institute For Biological Studies Crf analogs
EP0860501A3 (fr) 1994-06-14 1999-05-19 Neurocrine Biosciences, Inc. Récepteurs du facteur 2 libérant la corticotropine
US5786203A (en) 1994-06-14 1998-07-28 Neurocrine Biosciences, Inc. Isolated nucleic acid encoding corticotropin-releasing factor2 receptors
US5663292A (en) 1994-12-12 1997-09-02 The Salk Institute For Biological Studies Cyclic CRF analogs
US5824771A (en) 1994-12-12 1998-10-20 The Salk Institute For Biological Studies Cyclic CRF agonists
US5660824A (en) 1995-05-24 1997-08-26 Grabstein; Kenneth H. Muscle trophic factor
CA2223792A1 (fr) 1995-06-13 1997-01-03 The Salk Institute For Biological Studies Peptides d'urocortine
AU2001284683B2 (en) 2000-08-04 2006-04-27 Research Development Foundation Urocortin proteins and uses thereof
US20020082409A1 (en) 2000-10-26 2002-06-27 Hsu Sheau Yu Stresscopins and their uses
US6670140B2 (en) * 2001-03-06 2003-12-30 The Procter & Gamble Company Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors
US7192924B2 (en) * 2002-01-16 2007-03-20 The Procter & Gamble Company Corticotropin releasing factor 2 receptor agonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997032898A1 (fr) * 1996-03-06 1997-09-12 The Regents Of The University Of California Analogues anti-inflammatoires de crf, leur composition et leur emploi

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ASSIL IMAN Q ET AL: "An oxidation resistant radioligand for corticotropin-releasing factor receptors.", PEPTIDES (NEW YORK), vol. 22, no. 7, July 2001 (2001-07-01), pages 1055 - 1061, XP002244725, ISSN: 0196-9781 *
BEYERMANN MICHAEL ET AL: "A single-point slight alteration set as a tool for structure-activity relationship studies of ovine corticotropin releasing factor.", JOURNAL OF MEDICINAL CHEMISTRY, vol. 39, no. 17, 1996, pages 3324 - 3330, XP002244722, ISSN: 0022-2623 *
DAUTZENBERG FRANK M ET AL: "The CRF peptide family and their receptors: Yet more partners discovered.", TRENDS IN PHARMACOLOGICAL SCIENCES, vol. 23, no. 2, 20 February 2002 (2002-02-20), pages 71 - 77, XP002244726, ISSN: 0165-6147 *
ECKART KLAUS ET AL: "A single amino acid serves as an affinity switch between the receptor and the binding protein of corticotropin-releasing factor: Implications for the design of agonists and antagonists.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 98, no. 20, 25 September 2001 (2001-09-25), September 25, 2001, pages 11142 - 11147, XP002244721, ISSN: 0027-8424 *
KORNREICH W D ET AL: "ALANINE SERIES OF OVINE CORTICOTROPIN RELEASING FACTOR (OCRF): A STRUCTURE-ACTIVITY RELATIONSHIP STUDY", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 35, no. 10, 1992, pages 1870 - 1876, XP002030859, ISSN: 0022-2623 *
LEWIS K ET AL: "Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 98, no. 13, 19 June 2001 (2001-06-19), June 19, 2001, pages 7570 - 7575, XP002244720, ISSN: 0027-8424 *
REYES T M ET AL: "Urocortin II: A member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 98, no. 5, 27 February 2001 (2001-02-27), February 27, 2001, pages 2843 - 2848, XP002244723, ISSN: 0027-8424 *
RUHMANN ANDREAS ET AL: "Structural requirements for peptidic antagonists of the corticotropin-releasing factor receptor (CRFR): Development of CRFR2beta-selective antisauvagine-30.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 95, no. 26, 22 December 1998 (1998-12-22), Dec. 22, 1998, pages 15264 - 15269, XP002244724, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
EP1465921B1 (fr) 2006-07-26
MXPA04006884A (es) 2004-12-06
MXPA04006883A (es) 2004-12-06
HK1078095A1 (en) 2006-03-03
US7897731B2 (en) 2011-03-01
PL373529A1 (en) 2005-09-05
TW200302278A (en) 2003-08-01
EP1465922B1 (fr) 2008-01-09
DE60307044T2 (de) 2007-02-15
ES2269976T3 (es) 2007-04-01
EP1724283B1 (fr) 2008-06-18
US6936585B2 (en) 2005-08-30
AR038143A1 (es) 2004-12-29
JP4489434B2 (ja) 2010-06-23
TW200302276A (en) 2003-08-01
ES2299701T3 (es) 2008-06-01
CA2470731A1 (fr) 2003-07-31
NO20043396L (no) 2004-10-06
SA03230565A (ar) 2005-12-03
EP1465921A2 (fr) 2004-10-13
CA2470731C (fr) 2011-06-21
US7192923B2 (en) 2007-03-20
PT1465921E (pt) 2006-12-29
ES2287484T3 (es) 2007-12-16
NZ533598A (en) 2007-03-30
IL162431A0 (en) 2005-11-20
PE20030747A1 (es) 2003-10-23
BR0306838A (pt) 2005-04-05
US7608701B2 (en) 2009-10-27
RU2004124847A (ru) 2005-04-20
KR100758858B1 (ko) 2007-09-14
EP1465923B1 (fr) 2007-05-16
US20030148957A1 (en) 2003-08-07
PL373139A1 (en) 2005-08-22
KR20040082390A (ko) 2004-09-24
IL162530A0 (en) 2005-11-20
EP1465922A2 (fr) 2004-10-13
WO2003062268A3 (fr) 2003-11-27
US7462597B2 (en) 2008-12-09
DE60318547D1 (de) 2008-02-21
TW200302277A (en) 2003-08-01
DE60313845D1 (de) 2007-06-28
TWI300442B (en) 2008-09-01
NZ533600A (en) 2007-02-23
CN1617886A (zh) 2005-05-18
MXPA04006885A (es) 2004-12-06
ATE334147T1 (de) 2006-08-15
CA2470656C (fr) 2011-06-28
CN100391972C (zh) 2008-06-04
AU2003205197B2 (en) 2006-03-02
ATE362488T1 (de) 2007-06-15
US20090124793A1 (en) 2009-05-14
US20080004435A1 (en) 2008-01-03
IL196384A0 (en) 2011-07-31
PE20030849A1 (es) 2003-12-01
EP1724283A2 (fr) 2006-11-22
US20030148958A1 (en) 2003-08-07
AR038144A1 (es) 2004-12-29
IL197774A0 (en) 2009-12-24
DE60307044D1 (de) 2006-09-07
SA03230564A (ar) 2005-12-03
MA27590A1 (fr) 2005-11-01
EP1465923A1 (fr) 2004-10-13
JP4508649B2 (ja) 2010-07-21
CN1617887A (zh) 2005-05-18
SA03230564B1 (ar) 2006-10-31
JP4508648B2 (ja) 2010-07-21
PT1465923E (pt) 2007-08-06
AR038142A1 (es) 2004-12-29
NZ533599A (en) 2007-03-30
DE60318547T2 (de) 2008-12-24
BR0306826A (pt) 2005-09-06
WO2003062268A2 (fr) 2003-07-31
CA2470656A1 (fr) 2003-07-31
MA27591A1 (fr) 2005-11-01
MY140306A (en) 2009-12-31
CN1617885A (zh) 2005-05-18
ES2309909T3 (es) 2008-12-16
CN100475844C (zh) 2009-04-08
US7632933B2 (en) 2009-12-15
MA27592A1 (fr) 2005-11-01
US20100197579A1 (en) 2010-08-05
PL371364A1 (en) 2005-06-13
KR100735586B1 (ko) 2007-07-04
DE60313845T2 (de) 2008-01-31
SI1465921T1 (sl) 2006-10-31
CA2470743C (fr) 2011-12-13
ATE398632T1 (de) 2008-07-15
BR0306878A (pt) 2004-10-26
DK1465921T3 (da) 2006-11-27
AU2003237419B2 (en) 2006-04-13
JP2005522191A (ja) 2005-07-28
WO2003062269A2 (fr) 2003-07-31
CY1106133T1 (el) 2011-06-08
JP2005525101A (ja) 2005-08-25
WO2003062277A1 (fr) 2003-07-31
KR20040082392A (ko) 2004-09-24
SA03230565B1 (ar) 2006-10-31
KR20040082389A (ko) 2004-09-24
PE20030974A1 (es) 2003-12-26
ZA200404995B (en) 2005-06-29
US20060025339A1 (en) 2006-02-02
ATE383372T1 (de) 2008-01-15
US7192924B2 (en) 2007-03-20
US20030148956A1 (en) 2003-08-07
DK1465923T3 (da) 2007-07-02
EP1724283A3 (fr) 2007-04-11
NO20043366L (no) 2004-10-06
NO20043371L (no) 2004-10-06
RU2294333C2 (ru) 2007-02-27
KR100758857B1 (ko) 2007-09-14
CA2470743A1 (fr) 2003-07-31
DE60321730D1 (de) 2008-07-31
JP2005521387A (ja) 2005-07-21
IL162529A0 (en) 2005-11-20

Similar Documents

Publication Publication Date Title
WO2003062269A3 (fr) Agonistes du recepteur 2 du facteur de liberation de la corticotropine
AU2003299791A1 (en) Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
WO2000043032A3 (fr) Baff, agents bloquants associes et utilisation de ceux-ci pour stimuler et inhiber la reponse immunitaire des lymphocytes b et des immunoglobulines
ZA200201806B (en) Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof.
AU4903101A (en) Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
AU2003265589A1 (en) Process for the preparation of 1,1,1,2,2-pentafluoroethane
WO2004058153A9 (fr) Methodes et compositions de traitement de cancer au moyen des genes 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 3922
MXPA01008148A (es) Derivados de epotilona, metodo para su produccion y su uso farmaceutico.
AU2003299648A1 (en) Substituted 4-phenyl-(1,3)-dioxanes
AU2001246536A1 (en) Polyamide nucleic acid derivatives, agents and methods for producing the same
ZA200208346B (en) Polyamide nucleic acid derivatives, agents and methods for producing the same.
AU2003289176A1 (en) 1,3-benzothiazinone derivatives, process for producing the same and use thereof
AU2002325164A1 (en) Receptor, the use thereof, and mouse antibodies
HUP0201035A2 (en) Substituted bezimidazole, the production thereof and the use thereof as means against parasitic protozoa
PL377292A1 (pl) Ulepszony sposób wytwarzania 1,3-podstawionych indenów
AU2003223992A1 (en) Solid stabilizer composition, the production and the use thereof
AU2001252254A1 (en) 2,6-diamino-6-methyl-heptanoic acid and derivatives, process for the preparationthereof and use thereof
AU2002348998A1 (en) N-methyl-homocystines, use thereof and method for the production thereof
AU2001268108A1 (en) Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
WO1999053091A3 (fr) Adn codant pour le gdnf, parties de cet adn et variantes du gdnf
MXPA03007550A (es) Derivados coloporosidos, proceso para su preparacion y su uso.
AU2002330365A1 (en) "copolymer, coating composition comprising the same, process for applying it"
WO2000073345A3 (fr) Anticorps specifiques des polypeptides mycobacteriens et leurs utilisations
AU2003249999A1 (en) 1,4,7,10-tetraazacyclododecanes as modulators of the guanine-binding protein for treating tumours
AU2003235442A1 (en) 3-aza- and 1,4-diaza-bicyclo(4.3.0)nonanes, and methods of use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 162431

Country of ref document: IL

Ref document number: 1200400567

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 2470743

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 533600

Country of ref document: NZ

Ref document number: 1728/DELNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2004/04993

Country of ref document: ZA

Ref document number: 200404993

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2003703867

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1-2004-501012

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2003205197

Country of ref document: AU

Ref document number: PA/a/2004/006885

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2003562146

Country of ref document: JP

Ref document number: 20038023709

Country of ref document: CN

Ref document number: 1020047011051

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2003703867

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2003703867

Country of ref document: EP